The APS Foundation of America, Inc. is the only United States nonprofit health agency dedicated to bringing national awareness to Antiphospholipid Antibody Syndrome (APS), the major cause of multiple miscarriages, thrombosis, young strokes and heart attacks. We are a volunteer run, community based 501(c)3 non-profit Public Charity organization and is dedicated to fostering and facilitating joint efforts in the areas of education, support, public awareness, research and patient services.

A forum run by Heidi & Tina founders of the APS Foundation of America, Inc., a non profit organization. This forum is an information source and a friendly support group for people who have Antiphospholipid Antibody Syndrome or for anyone who's lives are touched by it. It is sometimes referred to as APS, APLS, or APLA and is known as Hughes Syndrome or "Sticky Blood" in the UK. APS is associated with recurrent clotting events including premature stroke, repeated miscarriages, phlebitis, venous thrombosis and pulmonary thromboembolism. If this disease touches your life in some way, please feel free to join in our discussions! :) We're glad to have you visit!

The Thrombosis Interest Group of Canada consists of a group of 40 specialists in fields related to thrombosis who collaborate to write evidence-based or consensus-based clinical guides on the investigation, management, and diagnosis of thrombotic disorders.

The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease risk, disease severity and activity, and clinical outcome, while also encouraging development of new approaches to diagnosis, prevention, and treatment.

A forum run by the APS Foundation of America, Inc., a non profit organization. This forum is an information source and a friendly support group for people who have Antiphospholipid Antibody Syndrome or for anyone who's lives are touched by it. It is sometimes referred to as APS, APLS, or APLA and is known as Hughes Syndrome or "Sticky Blood" in the UK. APS is associated with recurrent clotting events including premature stroke, repeated miscarriages, phlebitis, venous thrombosis and pulmonary thromboembolism. If this disease touches your life in some way, please feel free to join in our discussions! :) We're glad to have you visit!

Neuroland

© 2003. The Journal of Rheumatology Publishing Company Limited.

Written to inform Dentists about treating Warfarin Patients

Last Updated: October 26, 2004 Promtes an INR in the range of 2.5-3.5.

What if APS Foundation of America - APSFA earned a penny every time you searched the Internet? Well, now we can! GoodSearch.com is a new search engine that donates half its revenue, about a penny per search, to the charities its users designate. You use it just as you would any search engine, and it's powered by Yahoo!, so you get great results. Just go to http://www.goodsearch.com and be sure to enter APS Foundation of America - APSFA as the charity you want to support. Just 500 of us searching four times a day will raise about $7300 in a year without anyone spending a dime! And, be sure to spread the word!

Last Updated: December 5, 2004 Author: Steven Carsons, MD, Chief, Division of Rheumatology, Allergy, and Immunology, Professor of Medicine, Department of Internal Medicine, Winthrop University Hospital, State University of New York at Stony Brook

Circulation. 2005;112:e39-e44. © 2005 American Heart Association, Inc. Caron P. Misita, PharmD; Stephan Moll, MD

HIGHLY recommended! This jewerly could save your life!

Last Updated: December 5, 2004 Based on the most recent evidence, a reasonable target for the international normalized ratio (INR) is 2.6-3 for a minimum of 6 months for a first thrombosis. Patients with recurrent thrombotic events while well maintained on the above regimen may require an INR of 3-4 and generally receive anticoagulation therapy for life. For severe or refractory cases, a combination of warfarin and aspirin may be used.

The Rare Thrombotic Diseases Consortium (RTDC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of and improving the care of patients with thrombotic diseases. Funded by the National Institutes of Health (NIH), the RTDC is part of the Rare Diseases Clinical Research Network. The operations of the RTDC are directed from Duke University. Other primary RTDC study sites include the University of North Carolina, University of Wisconsin, Centers for Disease Control and Prevention, and the Mayo Clinic.

PDF File from the New England Journal of Medicine

© 2003. The Journal of Rheumatology Publishing Company Limited. Promotes an INR of greater than 3.0.

The Journal of Rheumatology Feb. 2005

Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of anticoagulant therapy.

The mission of the National Blood Clot Alliance is to prevent, diagnose and treat thrombosis and thrombophilia through research, education, support and advocacy.

by Erik Letko, M.D. Promotes an INR of greater that 3.0.

The Journal of Rheumatology Feb. 2005 Promotes an INR of greater than 3.0.